利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.051 秒)

    Amyloid &bgr; protein (globular assembly and uses thereof)
    12.
    发明授权
    Amyloid &bgr; protein (globular assembly and uses thereof) 失效
    淀粉样蛋白β蛋白（球状组装及其用途）

    公开(公告)号：US06218506B1

    公开(公告)日：2001-04-17

    申请号：US08796089

    申请日：1997-02-05

    申请人： Grant A. Krafft ,  William L. Klein ,  Brett A. Chromy ,  Mary P. Lambert ,  Caleb E. Finch ,  Todd Morgan ,  Pat Wals ,  Irina Rozovsky ,  Ann Barlow

    发明人： Grant A. Krafft ,  William L. Klein ,  Brett A. Chromy ,  Mary P. Lambert ,  Caleb E. Finch ,  Todd Morgan ,  Pat Wals ,  Irina Rozovsky ,  Ann Barlow

    IPC分类号： A61K3816

    CPC分类号： C07K14/4711 ,  A61K38/00

    摘要： The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid &bgr; peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.

    摘要翻译： 在本公开中描述的本发明涉及物质的新组合物，淀粉样蛋白β衍生的痴呆配体（ADDL's）。 ADDL由组装成能够激活特异性细胞过程的可溶性球状非纤维寡聚结构的淀粉样蛋白β肽组成。 本发明还包括用于测定ADDL的形成，存在，受体蛋白结合和细胞活性的方法。 本发明还包括由ADDL激活的细胞信号分子的测定方法和抑制剂分子。 还描述了阻断促进ADDL形成的蛋白质的分子。

    ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
    13.
    发明授权
    ADDL receptor polypeptides, polynucleotides and host cells for recombinant production 有权
    ADDL受体多肽，多核苷酸和用于重组生产的宿主细胞

    公开(公告)号：US09217024B2

    公开(公告)日：2015-12-22

    申请号：US12745887

    申请日：2008-12-17

    申请人： Jasna Jerecic ,  Grant A. Krafft

    发明人： Jasna Jerecic ,  Grant A. Krafft

    IPC分类号： A61P25/28 ,  A61P25/00 ,  A61K39/395 ,  C07K14/705

    CPC分类号： C07K14/705

    摘要： This invention provides a novel receptor expressed on neuronal cells in a developmentally-specific manner. Accordingly, this invention provides the amino acid sequences of selected portions of the receptor and polynucleotides encoding these portions as well as antibodies that bind to the polypeptide portions of the receptor. Compositions and methods for using the compositions are also provided.

    摘要翻译： 本发明提供了以发育特异性方式在神经细胞上表达的新型受体。 因此，本发明提供受体的选定部分的氨基酸序列和编码这些部分的多核苷酸以及结合受体多肽部分的抗体。 还提供了组合物和使用该组合物的方法。

    Amyloid beta-derived diffusible ligands (ADDLs), ADDL-surrogates, ADDL-binding molecules, and uses thereof
    15.
    发明申请
    Amyloid beta-derived diffusible ligands (ADDLs), ADDL-surrogates, ADDL-binding molecules, and uses thereof 审中-公开
    淀粉样蛋白β衍生的扩散性配体（ADDL），ADDL代用品，ADDL结合分子及其用途

    公开(公告)号：US20080176252A1

    公开(公告)日：2008-07-24

    申请号：US11142869

    申请日：2005-06-01

    申请人： Grant A. Krafft ,  William L. Klein ,  David W. Summa ,  Brett A. Chromy ,  Lei Chang ,  Mary P. Lambert ,  Kirsten L. Viola ,  Yuesong Gong

    发明人： Grant A. Krafft ,  William L. Klein ,  David W. Summa ,  Brett A. Chromy ,  Lei Chang ,  Mary P. Lambert ,  Kirsten L. Viola ,  Yuesong Gong

    IPC分类号： G01N33/567 ,  G01N33/566

    CPC分类号： G01N33/6896 ,  C07K16/18

    摘要： The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.

    摘要翻译： 本文的发明包括淀粉样蛋白β衍生的扩散配体（ADDL），包含ADDL的组合物，ADDL替代物，ADDL结合分子，以及使用任何前述化合物和组合物的方法。 ADDL包含组装成能够激活特异性细胞过程的可溶性，球状，非纤维状，寡聚结构的淀粉样蛋白β蛋白。 本发明还包括产生ADDL特异性抗体的方法和使用ADDL特异性抗体测定ADDL的形成，存在，受体蛋白结合和细胞活性的方法，以及使用这些抗体来检测阻断形成或活性的化合物 的ADDLs，以及鉴定这些化合物的方法。 本发明还提供使用ADDL特异性抗体调节ADDL形成和/或活性的方法，特别是在治疗学习和/或记忆障碍方面。

    ADDL Binding to Hippocampal Neurons
    16.
    发明申请
    ADDL Binding to Hippocampal Neurons 审中-公开
    ADDL与海马神经元的结合

    公开(公告)号：US20080014596A1

    公开(公告)日：2008-01-17

    申请号：US11560834

    申请日：2006-11-16

    申请人： Jasna Jerecic ,  Grant A. Krafft

    发明人： Jasna Jerecic ,  Grant A. Krafft

    IPC分类号： G01N33/567 ,  G01N33/53

    CPC分类号： G01N33/5058 ,  G01N2333/4709 ,  G01N2800/2821

    摘要： Disclosed herein are methods for the quantification of ADDL binding to neuronal cells, including, but not limited to, primary cultures of hippocampal neurons. The method identifies and selects neurons based on any means capable of distinguishing neuronal cells, including, but not limited to, MAP2 immunoreactivity, which ensures that glial cells are excluded from an ADDL binding analysis; antibodies selective for neuronal cell surface receptors and/or other surface markers; reagents specific for neuronal signalling markers present intracellularly; and the like. Furthermore, ADDL binding occurs in a sub-population of 16 DIV neurons and is heterogeneous in intensity among individual cells. Also, ADDL binding can be further specified and quantified by using additional markers. Additionally, the presence or absence of ADDL binding is used to identify, characterize, analyze, assess, and/or evaluate agents (e.g., including, but not limited to, small molecules, antibodies, chemical compounds, dietary components, environmental conditions, etc.) that modulate ADDL binding. Such modulation can be positive or negative, including, but not limited to, ADDL binding inhibition, either total inhibition or partial inhibition, and the like.

    摘要翻译： 本文公开了用于定量ADDL与神经元细胞结合的方法，包括但不限于海马神经元的原代培养物。 该方法基于能够区分神经元细胞的任何手段识别和选择神经元，包括但不限于MAP2免疫反应性，其确保从ADDL结合分析中排除胶质细胞; 对神经元细胞表面受体和/或其他表面标记物有选择性的抗体; 特异于神经元信号标记的试剂存在于细胞内; 等等。 此外，ADDL结合发生在16个DIV神经元的亚群中，并且在各个细胞之间的强度异质性。 此外，可以通过使用额外的标记进一步指定和量化ADDL结合。 此外，ADDL结合的存在或不存在用于鉴定，表征，分析，评估和/或评价试剂（例如，包括但不限于小分子，抗体，化合物，饮食组分，环境条件等） 。）调制ADDL绑定。 这种调节可以是阳性或阴性，包括但不限于ADDL结合抑制，总抑制或部分抑制等。